Piper Sandler Maintains Neutral on Medtronic, Raises Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains a Neutral rating on Medtronic (NYSE:MDT) and raises the price target from $85 to $90.
August 21, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has maintained a Neutral rating on Medtronic but increased the price target from $85 to $90, indicating a slightly more positive outlook.
The increase in price target from $85 to $90 suggests a slightly more optimistic view on Medtronic's stock performance, which could lead to a positive short-term impact on the stock price. However, the Neutral rating indicates that the analyst does not expect significant outperformance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100